Hofseth BioCare has announced breakthrough results for its patented OmeGo salmon oil following a 14-week head-to-head clinical trial. The study demonstrated that the Norwegian company’s product increased a widely used biomarker of omega-3 status by over 70% compared to a competing product. OmeGo is derived from Atlantic salmon and represents a significant advancement in marine-based nutritional supplements and functional ingredients. The results suggest superior bioavailability or efficacy compared to standard omega-3 supplements on the market. This development could strengthen Hofseth BioCare’s position in the growing global market for fish-derived health products and marine ingredients. The company specializes in upcycling marine by-products from salmon processing into high-value nutritional ingredients. The positive trial results may have significant implications for the broader fish oil and omega-3 supplement industry, potentially influencing consumer preferences, product formulations, and market dynamics for salmon-derived nutritional products competing against traditional fish oils.
Original source: Hofseth BioCare claims salmon oil breakthrough in head-to-head trial